Fondaparinux dosage forms and strengths: Difference between revisions

Revision as of 20:25, 3 March 2014

Fondaparinux
Arixtra^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Fondaparinux
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Single-dose, prefilled syringes containing either 2.5 mg, 5 mg, 7.5 mg, or 10 mg of fondaparinux.^[1]

Adapted from the FDA Package Insert.

Revision as of 20:08, 3 March 2014 view source Abdurahman Khalil (talk \| contribs) nocaptcha 3,981 edits No edit summary ← Older edit		Revision as of 20:25, 3 March 2014 view source Abdurahman Khalil (talk \| contribs) nocaptcha 3,981 edits No edit summary Newer edit →
Line 5:		Line 5:
	==Dosage Forms And Strengths==		==Dosage Forms And Strengths==

	~~'''~~Single-dose~~'''~~, prefilled syringes containing either ~~'''~~2.5 mg, 5 mg, 7.5 mg, or 10 mg~~'''~~ of fondaparinux.<ref name="dailymed.nlm.nih.gov">{{Cite web \| last = \| first = \| title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] \| url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f \| publisher = \| date = \| accessdate = }}</ref>		Single-dose, prefilled syringes containing either 2.5 mg, 5 mg, 7.5 mg, or 10 mg of fondaparinux.<ref name="dailymed.nlm.nih.gov">{{Cite web \| last = \| first = \| title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] \| url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f \| publisher = \| date = \| accessdate = }}</ref>